Antimicrobial stewardship in immunocompromised hosts

Infectious Disease Clinics of North America

Volumn 28, Issue 2, 2014, Pages 263-279

  Abbo, Lilian M ^a   Ariza Heredia, Ella J ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antimicrobial stewardship; Fever; Hematologic malignancies; Immunocompromised; Neutropenia; Solid organ; Transplant

Indexed keywords

AMPHOTERICIN; ANTIINFECTIVE AGENT; CARBAPENEM; CARBOPLATIN; CEFEPIME; CEPHALOSPORIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXTENDED SPECTRUM BETA LACTAMASE; FLUCONAZOLE; METHOTREXATE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOPOTECAN; VANCOMYCIN;

ADENOVIRUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ANTIVIRAL THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; GRAM NEGATIVE BACTERIUM; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFLUENZA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOSIS; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHINOVIRUS; RISK FACTOR; SCEDOSPORIUM APIOSPERMUM; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VIRUS IDENTIFICATION; VIRUS INFECTION; COMMUNICABLE DISEASES; DRUG UTILIZATION; EARLY DIAGNOSIS; INAPPROPRIATE PRESCRIBING; MULTIDRUG RESISTANCE; PREVENTION AND CONTROL; PROCEDURES; PROTOCOL COMPLIANCE; STANDARDS;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; DIAGNOSTIC TESTS, ROUTINE; DRUG RESISTANCE, MULTIPLE; DRUG UTILIZATION; EARLY DIAGNOSIS; GUIDELINE ADHERENCE; HUMANS; IMMUNOCOMPROMISED HOST; INAPPROPRIATE PRESCRIBING;

EID: 84901192169     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2014.01.008     Document Type: Review

References (110)

1. Poon L.M., Jin J., Chee Y.L., et al. Risk factors for adverse outcomes and multidrug-resistant gram-negative bacteraemia in haematology patients with febrile neutropenia in a singaporean university hospital. Singapore Med J 2012, 53(11):720-725.
2. Freifeld A.G., Bow E.J., Sepkowitz K.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011, 52(4):e56-e93.
3. Fishman J.A. Infection in solid-organ transplant recipients. NEngl J Med 2007, 357(25):2601-2614.
4. Marr K.A. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology 2012, 265-270.
5. Fishman J.A. Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transpl 2011, 17(Suppl 3):S34-S37.
6. Masterton R.G. Antibiotic heterogeneity. Int J Antimicrob Agents 2010, 36(Suppl 3):S15-S18.
7. Theodoropoulos N., Ison M.G. Current issues in transplant infectious diseases. Curr Infect Dis Rep 2013, 15(6):453-454.
8. Oliveira A.L., de Souza M., Carvalho-Dias V.M., et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007, 39(12):775-781.
9. Sifri C.D., Ison M.G. Highly resistant bacteria and donor-derived infections: treading in uncharted territory. Transpl Infect Dis 2012, 14(3):223-228.
10. Martin S.J., Micek S.T., Wood G.C. Antimicrobial resistance: consideration as an adverse drug event. Crit Care Med 2010, 38(Suppl 6):S155-S161.
11. McGowan J.E. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001, 7(2):286-292.
12. Maragakis L.L., Perencevich E.N., Cosgrove S.E. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6(5):751-763.
13. World Health Organization. The evolving threat of antimicrobial resistance. Options for action. World Health Organization. Available at:. Accessed October 28, 2012. http://www.who.int/patientsafety/implementation/amr/publication/en/index.html.
14. Aitken S.L., Palmer H.R., Topal J.E., et al. Call for antimicrobial stewardship in solid organ transplantation. Am J Transplant 2013, 13(9):2499.
15. Tverdek F.P., Rolston K.V., Chemaly R.F. Antimicrobial stewardship in patients with cancer. Pharmacotherapy 2012, 32(8):722-734.
16. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44(2):159-177.
17. Clancy C.J., Chen L., Shields R.K., et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant klebsiella pneumoniae in transplant recipients. Am J Transplant 2013, 13(10):2619-2633.
18. Cervera C., Linares L., Bou G., et al. Multidrug-resistant bacterial infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin 2012, 30(Suppl 2):40-48.
19. Shi S.H., Kong H.S., Xu J., et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009, 11(5):405-412.
20. Bergamasco M.D., Barroso Barbosa M., de Oliveira Garcia D., et al. Infection with klebsiella pneumoniae carbapenemase (kpc)-producing k. Pneumoniae in solid organ transplantation. Transpl Infect Dis 2012, 14(2):198-205.
21. Kalpoe J.S., Sonnenberg E., Factor S.H., et al. Mortality associated with carbapenem-resistant klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl 2012, 18(4):468-474.
22. Hammami S., Boutiba-Ben Boubaker I., Ghozzi R., et al. Nosocomial outbreak of imipenem-resistant pseudomonas aeruginosa producing vim-2 metallo-beta-lactamase in a kidney transplantation unit. Diagn Pathol 2011, 6:106.
23. Abbo A., Carmeli Y., Navon-Venezia S., et al. Impact of multi-drug-resistant acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007, 26(11):793-800.
24. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in enterobacteriaceae bacteraemia: a systematic review and meta-analysis. JAntimicrob Chemother 2007, 60(5):913-920.
25. Gudiol C., Calatayud L., Garcia-Vidal C., et al. Bacteraemia due to extended-spectrum beta-lactamase-producing escherichia coli (esbl-ec) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. JAntimicrob Chemother 2010, 65(2):333-341.
26. Gyssens I.C., Kern W.V., Livermore D.M., et al. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica 2013, 98(12):1821-1825.
27. Averbuch D., Cordonnier C., Livermore D.M., et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th european conference on infections in leukemia (ecil-4, 2011). Haematologica 2013, 98(12):1836-1847.
28. Bow E.J. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011, 24(6):545-553.
29. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for clostridium difficile-associated diarrhea: a cohort study during an epidemic in quebec. Clin Infect Dis 2005, 41(9):1254-1260.
30. Ananda-Rajah M.R., Slavin M.A., Thursky K.T. The case for antifungal stewardship. Curr Opin Infect Dis 2012, 25(1):107-115.
31. Graffunder E.M., Venezia R.A. Risk factors associated with nosocomial methicillin-resistant staphylococcus aureus (mrsa) infection including previous use of antimicrobials. JAntimicrob Chemother 2002, 49(6):999-1005.
32. Campillo B., Dupeyron C., Richardet J.P. Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001, 127(3):443-450.
33. Weber S.G., Gold H.S., Hooper D.C., et al. Fluoroquinolones and the risk for methicillin-resistant staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003, 9(11):1415-1422.
34. Liu W.L., Chang P.C., Chen Y.Y., et al. Fluoroquinolone use and resistance of gram-positive bacteria causing healthcare-associated infections. JAntimicrob Chemother 2012, 67(6):1560-1562.
35. Bodro M., Gudiol C., Garcia-Vidal C., et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant eskape pathogens in cancer patients. Support Care Cancer 2014, 22(3):603-610.
36. Prabhu R.M., Piper K.E., Litzow M.R., et al. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005, 24(12):832-838.
37. Yoo J.H., Huh D.H., Choi J.H., et al. Molecular epidemiological analysis of quinolone-resistant escherichia coli causing bacteremia in neutropenic patients with leukemia in korea. Clin Infect Dis 1997, 25(6):1385-1391.
38. Rangaraj G., Granwehr B.P., Jiang Y., et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010, 116(4):967-973.
39. Lautenbach E., Strom B.L., Bilker W.B., et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing escherichia coli and klebsiella pneumoniae. Clin Infect Dis 2001, 33(8):1288-1294.
40. Paterson D.L., Mulazimoglu L., Casellas J.M., et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000, 30(3):473-478.
41. Garnica M., Nouer S.A., Pellegrino F.L., et al. Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis 2013, 13(1):356.
42. Irfan S., Idrees F., Mehraj V., et al. Emergence of carbapenem resistant gram negative and vancomycin resistant gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 2008, 8:80.
43. Golledge C.L., Carson C.F., O'Neill G.L., et al. Ciprofloxacin and clostridium difficile-associated diarrhoea. JAntimicrob Chemother 1992, 30(2):141-147.
44. Weiss K. Clostridium difficile and fluoroquinolones: is there a link?. Int J Antimicrob Agents 2009, 33(Suppl 1):S29-S32.
45. Charbonneau P., Parienti J.J., Thibon P., et al. Fluoroquinolone use and methicillin-resistant staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006, 42(6):778-784.
46. Gafter-Gvili A., Fraser A., Paul M., et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012, (1). CD004386.
47. Roohullah A., Moniwa A., Wood C., et al. Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults. Intern Med J 2013, 43(10):1151-1154.
48. Paul M., Shani V., Muchtar E., et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010, 54(11):4851-4863.
49. Averbuch D., Orasch C., Cordonnier C., et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th european conference on infections in leukemia. Haematologica 2013, 98(12):1826-1835.
50. Kim W.J., Weinstein R.A., Hayden M.K. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. JInfect Dis 1999, 179(1):163-171.
51. DiazGranados C.A., Jernigan J.A. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. JInfect Dis 2005, 191(4):588-595.
52. Paul M., Borok S., Fraser A., et al. Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. JAntimicrob Chemother 2005, 55(4):436-444.
53. Chopra T., Alangaden G.J., Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2010, 8(10):1113-1119.
54. Dubberke E.R., Burdette S.D. Clostridium difficile infections in solid organ transplantation. Am J Transplant 2013, 13(Suppl 4):42-49.
55. Tamma P.D., Sandora T.J. Infection in children: current state and unanswered questions. JPediatric Infect Dis Soc 2012, 1(3):230-243.
56. Boutros M., Al-Shaibi M., Chan G., et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation 2012, 93(10):1051-1057.
57. Albright J.B., Bonatti H., Mendez J., et al. Early and late onset clostridium difficile-associated colitis following liver transplantation. Transpl Int 2007, 20(10):856-866.
58. Depestel D.D., Aronoff D.M. Epidemiology of clostridium difficile infection. JPharm Pract 2013, 26(5):464-475.
59. Charani E., Castro-Sanchez E., Sevdalis N., et al. Understanding the determinants of antimicrobial prescribing within hospitals: The role of prescribing etiquette. Clin Infect Dis 2013, 57(2):188-196.
60. Brecher S.M., Novak-Weekley S.M., Nagy E. Laboratory diagnosis of clostridium difficile infections: there is light at the end of the colon. Clin Infect Dis 2013, 57(8):1175-1181.
61. Mihu C.N., Paskovaty A., Seo S.K. Antimicrobial stewardship: considerations for a cancer center. Principles and practice of cancer infectious diseases. 2011, 491-498. Springer Science, Business Media, New York. A. Safdar (Ed.).
62. Standiford H.C., Chan S., Tripoli M., et al. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012, 33(4):338-345.
63. Shaikh Z.H., Osting C.A., Hanna H.A., et al. Effectiveness of a multifaceted infection control policy in reducing vancomycin usage and vancomycin-resistant enterococci at a tertiary care cancer centre. JHosp Infect 2002, 51(1):52-58.
64. Yeo C.L., Wu J.E., Chung G.W., et al. Specialist trainees on rotation cannot replace dedicated consultant clinicians for antimicrobial stewardship of specialty disciplines. Antimicrob Resist Infect Control 2012, 1(1):36.
65. Yeo C.L., Chan D.S., Earnest A., et al. Prospective audit and feedback on antibiotic prescription in an adult hematology-oncology unit in singapore. Eur J Clin Microbiol Infect Dis 2012, 31(4):583-590.
66. Cosgrove S.E., Seo S.K., Bolon M.K., et al. Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention. Infect Control Hosp Epidemiol 2012, 33(4):374-380.
67. Pakakasama S., Surayuthpreecha K., Pandee U., et al. Clinical practice guidelines for children with cancer presenting with fever to the emergency room. Pediatr Int 2011, 53(6):902-905.
68. Zuckermann J., Moreira L.B., Stoll P., et al. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 2008, 87(2):139-145.
69. Penack O., Buchheidt D., Christopeit M., et al. Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the german society of hematology and oncology. Ann Oncol 2011, 22(5):1019-1029.
70. National Institute for Healthcare and Excellence. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. Clinical guideline. Available at:. Accessed November 14, 2013. http://publications.nice.org.uk/neutropenic-sepsis-prevention-and-management-of-neutropenic-sepsis-in-cancer-patients-cg151.
71. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009, 44(8):453-558.
72. Cabrera-Cancio M.R. Infections and the compromised immune status in the chronically critically ill patient: prevention strategies. Respir Care 2012, 57(6):979-990. [discussion: 90-2].
73. Samore M.H., Bateman K., Alder S.C., et al. Clinical decision support and appropriateness of antimicrobial prescribing: a randomized trial. JAMA 2005, 294(18):2305-2314.
74. Madaras-Kelly K.J., Hannah E.L., Bateman K., et al. Experience with a clinical decision support system in community pharmacies to recommend narrow-spectrum antimicrobials, nonantimicrobial prescriptions, and otc products to decrease broad-spectrum antimicrobial use. JManag Care Pharm 2006, 12(5):390-397.
75. DiNubile M.J. Stopping antibiotic therapy in neutropenic patients. Ann Intern Med 1988, 108(2):289-292.
76. Horowitz H.W., Holmgren D., Seiter K. Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk Lymphoma 1996, 23(1-2):159-163.
77. Marra C.A., Frighetto L., Quaia C.B., et al. Anew ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis. Pharmacotherapy 2000, 20(8):931-940.
78. Lortholary O., Lefort A., Tod M., et al. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 2008, 8(10):612-620.
79. Denning D.W., Bowyer P. Voriconazole resistance in aspergillus fumigatus: should we be concerned?. Clin Infect Dis 2013, 57(4):521-523.
80. van der Linden J.W., Snelders E., Kampinga G.A., et al. Clinical implications of azole resistance in aspergillus fumigatus, the netherlands, 2007-2009. Emerg Infect Dis 2011, 17(10):1846-1854.
81. Cuenca-Estrella M., Alastruey-Izquierdo A., Alcazar-Fuoli L., et al. Invitro activities of 35 double combinations of antifungal agents against scedosporium apiospermum and scedosporium prolificans. Antimicrob Agents Chemother 2008, 52(3):1136-1139.
82. Nivoix Y., Velten M., Letscher-Bru V., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008, 47(9):1176-1184.
83. Yustes C., Guarro J. Invitro synergistic interaction between amphotericin b and micafungin against scedosporium spp. Antimicrob Agents Chemother 2005, 49(8):3498-3500.
84. Brizendine K.D., Vishin S., Baddley J.W. Antifungal prophylaxis in solid organ transplant recipients. Expert Rev Anti Infect Ther 2011, 9(5):571-581.
85. Avery R.K. Antifungal prophylaxis in lung transplantation. Semin Respir Crit Care Med 2011, 32(6):717-726.
86. Stanzani M., Battista G., Sassi C., et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis 2012, 54(5):610-616.
87. Cornely O.A., Aversa F., Cook P., et al. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur J Haematol 2011, 87(4):289-301.
88. Barnes R.A., Stocking K., Bowden S., et al. Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. JInfect 2013, 67(3):206-214.
89. Barnes R.A., White P.L., Bygrave C., et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. JClin Pathol 2009, 62(1):64-69.
90. Shah D.N., Yau R., Weston J., et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. JAntimicrob Chemother 2011, 66(9):2146-2151.
91. Apisarnthanarak A., Yatrasert A., Mundy L.M. Impact of education and an antifungal stewardship program for candidiasis at a thai tertiary care center. Infect Control Hosp Epidemiol 2010, 31(7):722-727.
92. Kotton C.N. Cmv: prevention, diagnosis and therapy. Am J Transplant 2013, 13(Suppl 3):24-40. [quiz: 40].
93. Kotton C.N., Kumar D., Caliendo A.M., et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013, 96(4):333-360.
94. Snydman D.R., Werner B.G., Heinze-Lacey B., et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. NEngl J Med 1987, 317(17):1049-1054.
95. Shah D.P., Ghantoji S.S., Mulanovich V.E., et al. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res 2012, 2(4):203-218.
96. Pelaez A., Lyon G.M., Force S.D., et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. JHeart Lung Transplant 2009, 28(1):67-71.
97. Li L., Avery R., Budev M., et al. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. JHeart Lung Transplant 2012, 31(8):839-844.
98. Park S.Y., Baek S., Lee S.O., et al. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. Antimicrob Agents Chemother 2013, 57(2):983-989.
99. Joffe S., Ray G.T., Escobar G.J., et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999, 104(3 Pt 1):419-427.
100. Wang D., Bayliss S., Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (rsv) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011, 15(5):iii-iiv. 1-124.
101. Kassis C., Champlin R.E., Hachem R.Y., et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant 2010, 16(9):1265-1271.
102. Afshari A., Schrenzel J., Ieven M., et al. Bench-to-bedside review: rapid molecular diagnostics for bloodstream infection - a new frontier?. Crit Care 2012, 16(3):222.
103. Laxminarayan R., Duse A., Wattal C., et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013, 13(12):1057-1098.
104. Goff D.A., Jankowski C., Tenover F.C. Using rapid diagnostic tests to optimize antimicrobial selection in antimicrobial stewardship programs. Pharmacotherapy 2012, 32(8):677-687.
105. Perez K.K., Olsen R.J., Musick W.L., et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med 2013, 137(9):1247-1254.
106. Tamma P.D., Tan K., Nussenblatt V.R., et al. Can matrix-assisted laser desorption ionization time-of-flight mass spectrometry (maldi-tof) enhance antimicrobial stewardship efforts in the acute care setting?. Infect Control Hosp Epidemiol 2013, 34(9):990-995.
107. Springer J., Morton C.O., Perry M., et al. Multicenter comparison of serum and whole-blood specimens for detection of aspergillus DNA in high-risk hematological patients. JClin Microbiol 2013, 51(5):1445-1450.
108. Holtzman C., Whitney D., Barlam T., et al. Assessment of impact of peptide nucleic acid fluorescence in situ hybridization for rapid identification of coagulase-negative staphylococci in the absence of antimicrobial stewardship intervention. JClin Microbiol 2011, 49(4):1581-1582.
109. Kim H., Hur M., Moon H.W., et al. Comparison of two multiplex pcr assays for the detection of respiratory viral infections. Clin Respir J 2013, [Epub ahead of print].
110. Mills J.M., Harper J., Broomfield D., et al. Rapid testing for respiratory syncytial virus in a paediatric emergency department: benefits for infection control and bed management. JHosp Infect 2011, 77(3):248-251.